IL128850A - Pharmaceutical composition comprising substituted or unsubstituted n, n-1[1-(4-chlorophenyl) cyclobutyl]-3-methylbutylamine hydrochloride monohydrate for reducing insulin resistance in humans and its manufacture - Google Patents

Pharmaceutical composition comprising substituted or unsubstituted n, n-1[1-(4-chlorophenyl) cyclobutyl]-3-methylbutylamine hydrochloride monohydrate for reducing insulin resistance in humans and its manufacture

Info

Publication number
IL128850A
IL128850A IL12885097A IL12885097A IL128850A IL 128850 A IL128850 A IL 128850A IL 12885097 A IL12885097 A IL 12885097A IL 12885097 A IL12885097 A IL 12885097A IL 128850 A IL128850 A IL 128850A
Authority
IL
Israel
Prior art keywords
cyclobutyl
chlorophenyl
unsubstituted
humans
substituted
Prior art date
Application number
IL12885097A
Other languages
English (en)
Other versions
IL128850A0 (en
Original Assignee
Abott Gmbh & Co Kg
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abott Gmbh & Co Kg filed Critical Abott Gmbh & Co Kg
Publication of IL128850A0 publication Critical patent/IL128850A0/xx
Publication of IL128850A publication Critical patent/IL128850A/xx

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/13Amines
    • A61K31/135Amines having aromatic rings, e.g. ketamine, nortriptyline
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/48Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Diabetes (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Electrotherapy Devices (AREA)
IL12885097A 1996-09-21 1997-09-15 Pharmaceutical composition comprising substituted or unsubstituted n, n-1[1-(4-chlorophenyl) cyclobutyl]-3-methylbutylamine hydrochloride monohydrate for reducing insulin resistance in humans and its manufacture IL128850A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9619757.9A GB9619757D0 (en) 1996-09-21 1996-09-21 Chemical process
PCT/EP1997/005039 WO1998011884A1 (en) 1996-09-21 1997-09-15 Use of sibutramine analogues to prevent the development of diabetes

Publications (2)

Publication Number Publication Date
IL128850A0 IL128850A0 (en) 2000-01-31
IL128850A true IL128850A (en) 2003-07-31

Family

ID=10800326

Family Applications (1)

Application Number Title Priority Date Filing Date
IL12885097A IL128850A (en) 1996-09-21 1997-09-15 Pharmaceutical composition comprising substituted or unsubstituted n, n-1[1-(4-chlorophenyl) cyclobutyl]-3-methylbutylamine hydrochloride monohydrate for reducing insulin resistance in humans and its manufacture

Country Status (26)

Country Link
US (3) US6174925B1 (ru)
EP (1) EP0927028A1 (ru)
JP (1) JP2001503737A (ru)
KR (1) KR20000048501A (ru)
CN (1) CN1237905A (ru)
AU (1) AU724488B2 (ru)
BG (1) BG64473B1 (ru)
BR (1) BR9711517A (ru)
CA (1) CA2266401C (ru)
CZ (1) CZ93699A3 (ru)
GB (1) GB9619757D0 (ru)
HR (1) HRP970505A2 (ru)
HU (1) HUP9904026A3 (ru)
ID (1) ID18320A (ru)
IL (1) IL128850A (ru)
MY (1) MY116150A (ru)
NO (1) NO991358D0 (ru)
NZ (1) NZ334580A (ru)
PL (1) PL332305A1 (ru)
RU (1) RU2245709C2 (ru)
SK (1) SK31999A3 (ru)
TR (1) TR199900618T2 (ru)
TW (1) TW580385B (ru)
UA (1) UA64726C2 (ru)
WO (1) WO1998011884A1 (ru)
ZA (1) ZA978450B (ru)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9619757D0 (en) * 1996-09-21 1996-11-06 Knoll Ag Chemical process
ATE318138T1 (de) * 1998-06-30 2006-03-15 Takeda Pharmaceutical Pharmazeutisches mittel zur behandlung von diabetes
JP2000080047A (ja) * 1998-06-30 2000-03-21 Takeda Chem Ind Ltd 医 薬
US6339106B1 (en) 1999-08-11 2002-01-15 Sepracor, Inc. Methods and compositions for the treatment and prevention of sexual dysfunction
US6476078B2 (en) * 1999-08-11 2002-11-05 Sepracor, Inc. Methods of using sibutramine metabolites in combination with a phosphodiesterase inhibitor to treat sexual dysfunction
US6331571B1 (en) 1998-08-24 2001-12-18 Sepracor, Inc. Methods of treating and preventing attention deficit disorders
US6974838B2 (en) 1998-08-24 2005-12-13 Sepracor Inc. Methods of treating or preventing pain using sibutramine metabolites
US20040102486A1 (en) * 1998-11-12 2004-05-27 Smithkline Beecham Corporation Novel method of treatment
DZ2937A1 (fr) * 1998-11-12 2004-03-15 Smithkline Beecham Plc Compositions nouvelles de sensibilidants à l'insuline.
WO2000028989A1 (en) * 1998-11-12 2000-05-25 Smithkline Beecham P.L.C. Pharmaceutical composition for modified release of an insulin sensitiser and another antidiabetic agent
US6696495B2 (en) 1998-12-02 2004-02-24 Snowden Pharmaceuticals, Llc Treatment of disorders secondary to organic impairments
US6323242B1 (en) 1998-12-02 2001-11-27 Peter Sterling Mueller Treatment of disorders secondary to organic impairments
US6552087B1 (en) 1999-03-19 2003-04-22 Abbott Gmbh & Co. Kg Therapeutic agent comprising (+)-sibutramine
US6723717B1 (en) 1999-06-01 2004-04-20 The University Of Texas Southwestern Medical Center Sulfur-containing thyroxane derivatives and their use as hair growth promotors
AU3712100A (en) 1999-06-01 2000-12-18 University Of Texas Southwestern Medical Center, The Method of treating hair loss using sulfonyl thyromimetic compounds
US6680344B1 (en) 1999-06-01 2004-01-20 The University Of Texas Southwestern Medical Center Method of treating hair loss using diphenylmethane derivatives
US6399826B1 (en) 1999-08-11 2002-06-04 Sepracor Inc. Salts of sibutramine metabolites, methods of making sibutramine metabolites and intermediates useful in the same, and methods of treating pain
WO2002083631A1 (en) * 2001-04-13 2002-10-24 Sepracor Inc. Methods of preparing didesmethylsibutramine and other sibutramine derivatives
KR100897890B1 (ko) 2002-06-17 2009-05-18 인벤티아 헬스케어 피브이티. 엘티디. 티아졸리딘디온 및 바이구아나이드를 함유하는 다층 정제및 그의 제조 방법
BR0315084A (pt) * 2002-10-05 2005-08-16 Hanmi Pharm Ind Co Ltd Composição farmacêutica compreendendo hemiidrato cristalino de metanossulfonato de sibutramina
US20050131074A1 (en) * 2003-08-04 2005-06-16 Beckman Kristen M. Methods for treating metabolic syndrome
UY28457A1 (es) * 2003-08-07 2005-03-31 Sb Pharmco Inc Nueva composición
GB0318824D0 (en) * 2003-08-11 2003-09-10 Glaxo Group Ltd Novel composition
AU2004285354B2 (en) * 2003-10-31 2009-09-17 Takeda Pharmaceutical Company Limited Solid preparation comprising an insulin sensitizer, an insulin secretagogue and a polyoxyethylene sorbitan fatty acid ester
KR100627687B1 (ko) * 2005-04-20 2006-09-25 주식회사 씨티씨바이오 시부트라민 유리염기 함유 조성물 및 이의 제조방법
CA2636324C (en) * 2006-01-06 2012-03-20 Sepracor Inc. Cycloalkylamines as monoamine reuptake inhibitors
JP2010503709A (ja) 2006-09-15 2010-02-04 レビバ ファーマシューティカルズ,インコーポレーテッド シクロアルキルメチルアミンの合成、使用方法および組成物
US8604244B2 (en) 2010-07-02 2013-12-10 Reviva Pharmaceuticals, Inc. Compositions, synthesis, and methods of using cycloalkylmethylamine derivatives
KR100812538B1 (ko) * 2006-10-23 2008-03-11 한올제약주식회사 약물 제어방출형 메트포르민-글리메피리드 복합제제
AU2007322477A1 (en) * 2006-11-22 2008-05-29 Sk Chemicals Co., Ltd. Inclusion complex of sibutramine and beta-cyclodextrin
DK2118123T3 (en) 2007-01-31 2016-01-25 Dana Farber Cancer Inst Inc Stabilized p53 peptides and uses thereof
ES2610531T3 (es) 2007-03-28 2017-04-28 President And Fellows Of Harvard College Polipéptidos cosidos
ES2711526T3 (es) 2010-08-13 2019-05-06 Aileron Therapeutics Inc Macrociclos peptidomiméticos
RU2639523C2 (ru) 2011-10-18 2017-12-21 Эйлерон Терапьютикс, Инк. Пептидомиметические макроциклы и их применение
KR20140110014A (ko) 2011-12-30 2014-09-16 레비바 파마슈티칼스, 아이엔씨. 페닐시클로알킬메틸아민 유도체의 조성물, 합성, 및 사용 방법
MX362492B (es) 2012-02-15 2019-01-21 Aileron Therapeutics Inc Macrociclos peptidomiméticos.
JP6450192B2 (ja) 2012-02-15 2019-01-09 エイルロン セラピューティクス,インコーポレイテッド トリアゾール架橋した、およびチオエーテル架橋したペプチドミメティック大環状化合物
AU2013337388B2 (en) 2012-11-01 2018-08-02 Aileron Therapeutics, Inc. Disubstituted amino acids and methods of preparation and use thereof
KR20170058424A (ko) 2014-09-24 2017-05-26 에일러론 테라퓨틱스 인코포레이티드 펩티드모방 거대고리 및 이의 용도
EP3294318A4 (en) 2015-03-20 2019-04-03 Aileron Therapeutics, Inc. PEPTIDOMIMETIC MACROCYCLES AND USES THEREOF

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IE52768B1 (en) * 1981-04-06 1988-02-17 Boots Co Ltd 1-arylcyclobutylalkylamine compounds useful as therapeutic agents
GB8531071D0 (en) * 1985-12-17 1986-01-29 Boots Co Plc Therapeutic compound
GB8704777D0 (en) * 1987-02-28 1987-04-01 Boots Co Plc Medical treatment
JP2675573B2 (ja) * 1988-03-31 1997-11-12 科研製薬株式会社 脳機能改善剤
IE61928B1 (en) * 1988-11-29 1994-11-30 Boots Co Plc Treatment of obesity
WO1995010292A1 (en) 1993-10-14 1995-04-20 Biomedica California, Inc. Diabetes treatment and prophylaxis
US5459164A (en) * 1994-02-03 1995-10-17 Boots Pharmaceuticals, Inc. Medical treatment
GB9619757D0 (en) * 1996-09-21 1996-11-06 Knoll Ag Chemical process

Also Published As

Publication number Publication date
BG64473B1 (bg) 2005-04-30
KR20000048501A (ko) 2000-07-25
JP2001503737A (ja) 2001-03-21
NZ334580A (en) 2000-09-29
CA2266401A1 (en) 1998-03-26
CZ93699A3 (cs) 1999-08-11
UA64726C2 (ru) 2004-03-15
PL332305A1 (en) 1999-08-30
NO991358L (no) 1999-03-19
AU724488B2 (en) 2000-09-21
GB9619757D0 (en) 1996-11-06
RU2245709C2 (ru) 2005-02-10
MY116150A (en) 2003-11-28
US6617360B1 (en) 2003-09-09
BG103277A (en) 2000-01-31
AU4774097A (en) 1998-04-14
HUP9904026A3 (en) 2000-07-28
EP0927028A1 (en) 1999-07-07
WO1998011884A1 (en) 1998-03-26
BR9711517A (pt) 1999-08-24
IL128850A0 (en) 2000-01-31
CA2266401C (en) 2007-01-30
ID18320A (id) 1998-03-26
HRP970505A2 (en) 1998-08-31
NO991358D0 (no) 1999-03-19
SK31999A3 (en) 1999-12-10
HUP9904026A2 (hu) 2000-05-28
US20040077730A1 (en) 2004-04-22
ZA978450B (en) 1999-03-19
TW580385B (en) 2004-03-21
CN1237905A (zh) 1999-12-08
TR199900618T2 (xx) 1999-06-21
US6174925B1 (en) 2001-01-16

Similar Documents

Publication Publication Date Title
IL128850A (en) Pharmaceutical composition comprising substituted or unsubstituted n, n-1[1-(4-chlorophenyl) cyclobutyl]-3-methylbutylamine hydrochloride monohydrate for reducing insulin resistance in humans and its manufacture
HUP0004300A3 (en) Pharmaceutical composition comprising (s)-n-ethyl-3-[1-(dimethylamino)ethyl]-n-methyl-phenyl-carbamate and an antioxidant
HUP0200522A3 (en) Triazole compounds with dopamine-d3-receptor affinity, pharmaceutical compositions containing them and their use
HU0500549D0 (en) Azolo-pyridimidines, pharmaceutical compositions containing the same and use thereof
HUP0100064A3 (en) Synergetic fungicidal combination comprising amides derivative and chlorothalonil and its use
HUP0400932A3 (en) Pharmaceutical composition containing nateglinide and another antidiabetic compound, process for its preparation and for use the same
PL313769A1 (en) Azole derivative and pharmaceutical composition thereof
HUP0000145A3 (en) Betha-sulfonyl hydroxamic acid derivatives with matrix maetalloproteinases inhibitor activity, use thereof and pharmaceutical compositions containing them
GB9520584D0 (en) Pyrazole derivatives,processes for preparation thereof and pharmaceutical composition comprising the same
ZA947710B (en) Imidazol-4 ylpiperdine derivatives, their preparation and their application in therapeutics.
IL123013A (en) Substituted imidazoles having biphenylsulfonyl substitution, and pharmaceutical compositions comprising them
HUP0100717A3 (en) Synergetic fungicidal composition comprising amide compound and its use
AU8278498A (en) Combination drug therapies comprising aminoglycoside antibiotics and n,n'-disubstituted guanidines
HUP0003063A3 (en) Synergetic fungicidal composition and its use
HUP0002361A3 (en) Synergetic fungicidal composition, based on halogenbenzimidazol derivative, manufacture and use thereof
IL118644A0 (en) N-Ú(1,4-diazabicyclo Ú2.2.2¾ oct-2-yl) methyl¾ benzamide derivatives their preparation and their application in therapeutics
HK1048917A1 (zh) 含有n-丙酮基苯甲酰胺和滅菌丹的殺真菌組合物
GB9310075D0 (en) New mercapto-amide derivatives,processes for the preparation thereof and pharmaceutical composition comprising the same
AU5922094A (en) 3-quinolyl-substituted dihydropyridines, processes for theirpreparation and their use in medicaments
EP0654479A3 (en) Esculetin derivatives, process for their preparation and their use as pharmaceutical compositions.
HUP0003074A3 (en) Pharmaceutical composition comprising ssri and betha-blocking agent
HUP0002975A3 (en) N-(4-acetyl-1-piperazinyl)-4-fluorobenzamide hydrate and pharmaceutical composition containing it
HUP0104623A3 (en) Cyclosporin solution, pharmaceutical composition comprising thereof and its use
HK1041689A1 (en) ((Aminoiminomethyl)amino) alkanecarboxamides and their applications in therapy.
HUP0004838A3 (en) Synergetic fungicidal combination comprising benzyl-ether derivative and n-acetonyl-benzamide derivative and its use

Legal Events

Date Code Title Description
HCA Change of name of proprietor(s) after amalgamation
FF Patent granted
KB Patent renewed
KB Patent renewed
KB Patent renewed
MM9K Patent not in force due to non-payment of renewal fees